Growth factors, AGEing, and the diabetes link in Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 16, Issue 4, 2009, Pages 823-831

  Loy, Clement T ^a,b   Twigg, Stephen M ^c,d  

^a NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Advanced glycation end products; Alzheimer's disease; Diabetes mellitus; Growth factors

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; CELL RECEPTOR; CONNECTIVE TISSUE GROWTH FACTOR; GROWTH FACTOR; INSULIN; NERVE GROWTH FACTOR; NEUROTROPHIC FACTOR; RECOMBINANT PLATELET DERIVED GROWTH FACTOR; SOMATOMEDIN C; VASCULOTROPIN; SIGNAL PEPTIDE;

AGING; ALZHEIMER DISEASE; DIABETES MELLITUS; DIABETIC FOOT; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; INSULIN METABOLISM; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; ANIMAL; METABOLISM;

AGING; ALZHEIMER DISEASE; ANIMALS; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS;

EID: 67649726060     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2009-0997     Document Type: Review

References (82)

1. Bucht H, Adolfsson R, Lithner K, Winblad B (1983) Changes in blood glucose and insulin secretion in patients with senile dementia of Alzheimer type. Acta Med Scand 213, 387-392.
2. Wolf-Klein GP, Siverstone FA, Brod MS, Levy A, Foley CJ, Termotto V, Breuer J (1988) Are Alzheimer patients healthier? J Am Geriatr Soc 36, 219-224. (Pubitemid 18078056)
3. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P (2006) Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 5, 64-74. (Pubitemid 41790697)
4. Brayne C, Gill C, Huppert FA, Barkley C, Gehlhaar E, Girling DM, O'Connor DW, Paykel ES (1998) Vascular risks and incident dementia: results from a cohort study of the very old. Dement Geriatr Cogn Disord 9, 175-180. (Pubitemid 28171890)
5. Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmen E, O'Brien PC, Palumbo PJ (1997) Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol 145, 301-308. (Pubitemid 27082028)
6. Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, Mayeux R (2005) Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 65, 545-551. (Pubitemid 41170713)
7. Ott A, StolkRP, van Harskamp F, Pols HA, Hofman A, Breteler MM (1999) Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 53, 1937-1942.
8. Peila R, Rodriguez BL, Launer LJ (2002) Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 51, 1256-1262. (Pubitemid 34438377)
9. Irie F, Fitzpatrick AL, Lopez OL, Kuller LH, Peila R, Newman AB, Launer LJ (2008) Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE epsilon4: the Cardiovascular Health Study Cognition Study. Arch Neurol 65, 89-93.
10. Yoshitake T, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K, Ohmori S, Nomiyama K, Kawano H, Ueda K, et al. (1995) Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: the Hisayama Study. Neurology 45, 1161-1168.
11. Akomolafe A, Beiser A, Meigs JB, Au R, Green RC, Farrer LA, Wolf PA, Seshadri S (2006) Diabetes mellitus and risk of developing Alzheimer disease: results from the Framingham Study. Arch Neurol 63, 1551-1555. (Pubitemid 44748797)
12. MacKnight C, Rockwood K, Awalt E, McDowell I (2002) Diabetes mellitus and the risk of dementia, Alzheimer's disease and vascular cognitive impairment in the Canadian Study of Health and Aging. Dement Geriatr Cogn Disord 14, 77-83. (Pubitemid 36152948)
13. Xu WL, Qiu CX, Wahlin A, Winblad B, Fratiglioni L (2004) Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology 63, 1181-1186. (Pubitemid 39350014)
14. Hassing LB, Johansson B, Nilsson SE, Berg S, Pedersen NL, Gatz M, McClearn G (2002) Diabetes mellitus is a risk factor for vascular dementia, but not for Alzheimer's disease: a population-based study of the oldest old. Int Psychogeriatr 14, 239-248. (Pubitemid 35375539)
15. Rönnemaa E, Zethelius B, Sundelö J, Sundström J, Degerman-Gunnarsson M, Berne C, Lannfelt L, Kilander L (2008) Impaired insulin secretion increases the risk of Alzheimer disease. Neurology 71, 1065-1071.
16. Katzman R, Aronson M, Fuld P, Kawas C, Brown T, Morgenstern H, Frishman W, Gidez L, Eder H, Ooi WL (1989) Development of dementing illnesses in an 80-year-old volunteer cohort. Ann Neurol 25, 317-324. (Pubitemid 19104162)
17. Arvanitakis Z, Schneider JA, Wilson RS, Li Y, Arnold SE, Wang Z, Bennett DA (2006) Diabetes is related to cerebral infarction but not to AD pathology in older persons. Neurology 67, 1960-1965. (Pubitemid 44967371)
18. Beeri MS, Silverman JM, Davis KL, Marin D, Grossman HZ, Schmeidler J, Purohit DP, Perl DP, Davidson M, Mohs RC, Haroutunian V (2005) Type 2 diabetes is negatively associated with Alzheimer's disease neuropathology. J Gerontol A Biol Sci Med Sci 60, 471-475. (Pubitemid 40712864)
19. Bennett SP, Griffiths GD, Schor AM, Leese GP, Schor SL (2003) Growth factors in the treatment of diabetic foot ulcers. Br J Surg 90, 133-146. (Pubitemid 36237887)
20. Wieman TJ, Smiell JM, Su Y (1998) Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor BB (becaplermin) in patients with chronic neuropathic ulcers. A phase III randomized placebo-controlled double blind study. Diabetes Care 21, 822-827.
21. Simo R, Hernandez C (2008) Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia 51, 1574-1580.
22. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356. (Pubitemid 34790756)
23. Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, Porte Jr. D (1998) Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 50, 164-168. (Pubitemid 28106036)
24. Lester-Coll N, Rivera EJ, Soscia SJ, Doiron K, Wands JR and de la Monte SM (2006) Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J Alzheimers Dis 9, 13-33.
25. Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, Fishel MA, Plymate SR, Breitner JC, DeGroodt W, Mehta P, Craft S (2008) Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 70, 440-448.
26. Carro E, Torres-Aleman I (2004) The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease. Eur J Pharmacol 490, 127-133. (Pubitemid 38482166)
27. Gasparini L, Gouras GK, Wang R, Gross RS, Beal MF, Greengard P, Xu H (2001) Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signalling. J Neurosci 21 (2001), 2561-2570. (Pubitemid 32298198)
28. Watson GS, Peskind ER, Asthana S, Purganan K, Wait C, Chapman D, Schwartz MW, Plymate S, Craft S (2003) Insulin increases CSF Abeta42 levels in normal older adults. Neurology 60, 1899-1903. (Pubitemid 36736003)
29. Hong M, Lee VM (1997) Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J Biol Chem 272, 19547-19553. (Pubitemid 27337756)
30. Tham A, Nordberg A, Grissom FE, Carlsson-Skwirut C, Viitanen M, Sara VR (1993) Insulin-like growth factors and insulin-like growth factor binding proteins in cerebrospinal fluid and serum of patients with dementia of the Alzheimer type. J Neural Transm Park Dis Dement Sect 5, 165-176. (Pubitemid 23227810)
31. Carro E, Trejo JL, Gomez-Isla T, LeRoith D, Torres-Aleman I (2002) Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat Med 8, 1390-1397. (Pubitemid 36019424)
32. Carro E, Trejo JL, Spuch C, Bohl D, Heard JM, Torres-Aleman I (2006) Blockade of the insulin-like growth factor I receptor in the choroid plexus originates Alzheimer's-like neuropathology in rodents: new cues into the human disease? Neurobiol Aging 27, 1618-1631. (Pubitemid 44344848)
33. Alvarez A, Cacabelos R, Sanpedro C, Garcia-Fantini M, Aleixandre M (2007) Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease. Neurobiol Aging 28, 533-536. (Pubitemid 46282207)
34. Williams BJ, Eriksdotter-Jonhagen M, Granholm AC (2006) Nerve growth factor in treatment and pathogenesis of Alzheimer's disease. Prog Neurobiol 80, 114-128. (Pubitemid 44739167)
35. Capsoni S, Cattaneo A (2006) On the molecular basis linking Nerve Growth Factor (NGF) to Alzheimer's disease. Cell Mol Neurobiol 26, 619-633.
36. Scott SA, Mufson EJ, Weingartner JA, Skau KA, Crutcher KA (1995) Nerve growth factor in Alzheimer's disease: increased levels throughout the brain coupled with declines in nucleus basalis. J Neurosci 15, 6213-6221.
37. Capsoni S, Giannotta S, Cattaneo A (2002) Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proc Natl Acad Sci U S A 99, 12432-12437.
38. Schindowski K, Belarbi K, Buee L (2008) Neurotrophic factors in Alzheimer's disease: role of axonal transport. Genes Brain Behav 7 Suppl 1, 43-56.
39. Phillips HS, Hains JM, Armanini M, Laramee GR, Johnson SA, Winslow JL (1991) BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron 7, 695-702.
40. Alzheimer Research Forum, Meta-Analysis of All Published AD Association Studies (Case-Control Only) rs6265, http://www.alzforum.org/res/com/gen/alzgene/ meta.asp?geneID=109, Accessed on November 24, 2008.
41. Garzon DJ, Fahnestock M (2007) Oligomeric amyloid decreases basal levels of brain-derived neurotrophic factor (BDNF) mRNA via specific downregulation of BDNF transcripts IV and V in differentiated human neuroblastoma cells. J Neurosci 27, 2628-2635.
42. Echeverria V, Berman DE, Arancio O (2007) Oligomers of beta-amyloid peptide inhibit BDNF-induced arc expression in cultured cortical neurons. Curr Alz Res 4, 518-521. (Pubitemid 350248384)
43. Christensen R, Marcussen AB, Wortwein G, Knudsen GM, Aznar S (2008) Abeta(1-42) injection causes memory impairment, lowered cortical and serum BDNF levels, and decreased hippocampal 5-HT(2A) levels. Exp Neurol 210, 164-171. (Pubitemid 351258077)
44. Elliott E, Atlas R, Lange A, Ginzburg I (2005) Brain-derived neurotrophic factor induces a rapid dephosphorylation of tau protein through a PI-3 Kinase signalling mechanism. Eur J Neurosci 22, 1081-1089. (Pubitemid 41395371)
45. Wyss-Coray T, Masliah E, Mallory M, McConlogue L, Johnson-Wood K, Lin C, Mucke, L (1997) Amyloidogenic role of cytokine TGF-beta1 in transgenic mice and in Alzheimer's disease. Nature 389, 603-606. (Pubitemid 27446177)
46. Grammas P, Ovase R (2002) Cerebrovascular transforming growth factor-beta contributes to inflammation in the Alzheimer's disease brain. Am J Pathol 160, 1583-1587. (Pubitemid 34525638)
47. Chalmers KA, Love S (2007) Neurofibrillary tangles may interfere with Smad 2/3 signaling in neurons. J Neuropathol Exp Neurol 66, 158-167.
48. Ueberham U, Ueberham E, Gruschka H, Arendt T (2006) Altered subcellular location of phosphorylated Smads in Alzheimer's disease. Eur J Neurosci 24, 2327-2334. (Pubitemid 44622353)
49. Das P, Golde T (2006) Dysfunction of TGF-β signaling in Alzheimer's disease. J Clin Invest 116, 2855-2857. (Pubitemid 44684467)
50. Salins P, He Y, Glazner G, Kashour T, Amara F (2008) TGF-beta1 is increased in a transgenic mouse model of familial Alzheimer's disease and causes neuronal apoptosis. Neurosci Lett 430, 81-86.
51. Town T, Laouar Y, Pittenger C, Mori T, Szekely CA, Tan J, Duman RS, Flavell RA (2008) Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat Med 14, 681-687. (Pubitemid 351809551)
52. Mateo I, Llorca J, Infante J, Rodriguez-Rodriguez E, Fernandez-Viadero C, Pena N, Berciano J, Combarros O (2007), Low serum VEGF levels are associated with Alzheimer's disease. Acta Neurol Scand 116, 56-58. (Pubitemid 46976267)
53. Yang S-P, Bae D-G, Kang HJ, Gwag BJ, Gho YS, Chae C-B (2004) Co-accumulation of vascular endothelial growth factor with beta-amyloid in the brain of patients with Alzheimer's disease. Neurobiol Aging 25, 283-290. (Pubitemid 38220962)
54. Zhao Z, Ho L, Wang J, Qin W, Festa ED, Mobbs C, Hof P, Rocher A, Masur S, Haroutunian V, Pasinetti GM(2005) Connective tissue growth factor (CTGF) expression in the brain is a downstream effector of insulin resistance- associated promotion of Alzheimer's disease beta-amyloid neuropathology. FASEB J 19, 2081-2082. (Pubitemid 41759772)
55. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, Schmidt AM(1996) RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382, 685-691. (Pubitemid 26282167)
56. Arancio O, Zhang HP, Chen X, Lin C, Trinchese F, Puzzo D, Liu S, Hegde A, Yan SF, Stern, A, Luddy JS, Lue L-F, Walker DG, Roher A, Buttini M, Mucke L, Li W, Schmidt AM, Kindy M, Hyslop PA, Stern DM, Du Yan SS (2004) RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J 23, 4096-4105. (Pubitemid 39472430)
57. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B (2003) RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9, 907-913. (Pubitemid 36889934)
58. Sturchler E, Galichet A, Weibel M, Leclerc E, Heizmann CW (2008) Site-specific blockade of RAGE-Vd prevents amyloid-beta oligomer neurotoxicity. J Neurosci 28, 5149-5158.
59. Sasaki N, Toki S, Chowei H, Saito T, Nakano N, Hayashi Y, Takeuchi M, Makita Z (2001) Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease. Brain Res 888, 256-262. (Pubitemid 32058790)
60. Bierhaus A, Hofmann MA, Ziegler R, Narworth PP (1998) AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res 37, 586-600. (Pubitemid 28231153)
61. Sasaki N, Fukatsu R, Tsuzuki K, Hayashi Y, Yoshida T, Fuji N, Koike T, Wakayama I, Yanagihara R, Garruto R, Amano N, Makita Z (1998) Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. Am J Pathol 153, 1149-1155. (Pubitemid 28465838)
62. Choei H, Sasaki N, Takeuchi M, Yoshida T, Ukai W, Yamagishi S, Kikuchi S, Saito T (2004) Glyceraldehyde-derived advanced glycation end products in Alzheimer's disease. Acta Neuropathol 108, 189-193. (Pubitemid 39199509)
63. Takeda A, Wakai M, Niwa H, Dei R, Yamamoto M, Li M, Goto Y, Yasuada T, Nakagomi Y, Watanabe M, Inagaki T, Yasuda Y, Miyata T, Sobue G (2001) Neuronal and glial advanced glycation end product [N epsilon-(carboxymethyl)lysine] in Alzheimer's disease brains. Acta Neuropathol 101, 27-35. (Pubitemid 32124497)
64. Girones X, Guimera A, Cruz-Sanchez CZ, Ortega A, Sasaki N, Makita Z, Lafuente JV, Kalaria R, Cruz-Sanchez FF (2004) N epsilon-carboxymethyl lysine in brain aging, diabetes mellitus, and Alzheimer's disease. Free Radic Biol Med 36, 1241-1247. (Pubitemid 38526318)
65. Takeuchi M, Yamagishi S (2008) Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease. Current Pharm Des, 14, 973-980. (Pubitemid 351753285)
66. Chen F, Wollmer MA, Hoerndli F, Munich G, Kuhla B, Rogaev EI, Tsolaki M, Papassotiropoulos M, Gotz J (2004) Role for glyoxalase I in Alzheimer's disease. Proc Natl Acad Sci USA 101, 7687-7692.
67. Münch G, Apelt J, Rosemarie-Kientsch-Engel, Stahl P, Luth HJ, Scliebs R (2003) Advanced glycation endproducts and pro-inflammatory cytokines in transgenic Tg2576 mice with amyloid plaque pathology. J Neurochem 86, 283-289. (Pubitemid 36842428)
68. Gasic-Milenkovic J, Dukic-Stefanovic S, Deuther-Conrad W, Gartner U, Munch G (2003) Beta-amyloid peptide potentiates inflammatory responses induced by lipopolysaccharide, interferon -gamma and 'advanced glycation endproducts' in a murine microglia cell line. Eur J Neurosci 17, 813-821. (Pubitemid 36315251)
69. Takeuchi M, Bucala R, Suzuki T, Ohkubo T, Yamazaki M, Koike T, Kameda Y, Makita Z (2000) Neurotoxicity of advanced glycation end-products for cultured cortical neurons. J Neuropathol Exp Neurol 59, 1094-1105. (Pubitemid 32006312)
70. Toth C, Schmidt AM, Tuor UI, Francis G, Foniok T, Brussee V, Kaur J, Yan SF, Martinez JA, Barber PA, Buchan A, Zochodne DW (2006) Diabetes, leukencephalopathy, and rage. Neurobiol Dis 23, 445-461.
71. Twigg SM, Joly AH, Chen MM, Tsubaki J, Kim HS, Hwa V, Oh Y, Rosenfeld RG (2002) Connective tissue growth factor/IGF-binding protein-related protein-2 is a mediator in the induction of fibronectin by advanced glycosylation end-products in human dermal fibroblasts. Endocrinology 143, 1260-1269. (Pubitemid 34274355)
72. Twigg SM, Cao Z, McLennan SV, Burns WC, Brammar G, Forbes JM, Cooper ME (2002) Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine. Endocrinology 143, 4907-4915. (Pubitemid 35397630)
73. Wilkinson-Berka JL, Kelly DJ, Koerner SM, Jaworski K, Davis B, Thallas V, Cooper ME (2002) ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2)27 rat. Diabetes 51, 3283-3289. (Pubitemid 35246975)
74. Twigg SM, Chen MM, Joly AH, Chakrapani SD, Tsubaki J, Kim HS, Oh Y, Rosenfeld RG (2001) Advanced glycosylation end products up-regulate connective tissue growth factor (insulin-like growth factor-binding protein-related protein 2) in human fibroblasts: a potential mechanism for expansion of extracellular matrix in diabetes mellitus. Endocrinology 142, 1760-1769. (Pubitemid 32405931)
75. Forbes JM, Thallas V, Thomas MC, Founds HW, Burns WC, Jerums G, Cooper ME (2003) The breakdown of pre-existing advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J 17, 1762-1764
76. Candido R, Forbes JM, Thomas MC, Thallas V, Dean RC, Burns WC, Tikellis C, Ritchie RH, Twigg SM, Cooper ME, Burrell LM (2003) A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res, 92, 785-792. (Pubitemid 36457644)
77. Goova MT, Li J, Kislinger T, Qu W, Lu Y, Bucciarelli LG, Nowygrod S, Wolf BM, Caliste X, Yan SF, Stern DM, Schmidt AM (2001) Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am J Pathol, 159, 513-525. (Pubitemid 32751082)
78. Lue LF, Walker DG, Brachova L, Beach TG, Rogers J, Schmidt AM, Stern DM, Yan SD (2001) Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp Neurol, 171, 29-45. (Pubitemid 32848443)
79. Yan SD, Zhu H, Fu J, Yan SF, Roher A, Tourtellotte WW, Rajavashisth T, Chen X, Godman GC, Stern D, Schmidt AM (1997) Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc Natl Acad Sci USA 94, 5296-5301. (Pubitemid 27214777)
80. Lesne S, Docagne F, Gabriel C, Liot G, Lahiri DK, Buee L, Plawinski L, Delacourte A, Mackenzie ET, Buisson A, VivienD(2003) Transforming growth factor-beta 1 potentiates amyloid-beta generation in astrocytes and in transgenic mice. J Biol Chem 278, 18408-18418.
81. Standridge JB (2006), Vicious cycles within the neuropathophysiologic mechanisms of Alzheimer's disease. Curr Alzheimer Res 3, 95-108.
82. Miyajima H, Osanai M, Chiba H, Nishikiori N, Kojima T, Ohtsuka K, Sawada. N (2005) Glyceraldehyde-derived advanced glycation end-products preferentially induce VEGF expression and reduce GDNF expression in human astrocytes. Biochem Biophys Res Commun 330, 361-366. (Pubitemid 40417654)